On Apr. 2, 2020, CHF Solutions announced it has doubled the production staff that builds its next generation Aquadex SmartFlow consoles in response to increased demand from hospitals due to the coronavirus COVID-19.

Following last week’s announcement regarding use of the Aquadex system in the treatment of critically ill patients, CHF Solutions has seen strong interest from additional hospitals and increased demand for this ultrafiltration therapy as the rate of affected patients continues to increase.

The World Health Organization (WHO) protocol for treating patients infected with COVID-19, highlights the need for effective fluid management treatment strategies when caring for the critical patient population because the risk of volume overload is very high. The Aquadex SmartFlow system is an efficient way of rapidly removing excess fluid from patients being treated with fluid resuscitation as part of the treatment for COVID-19.

CHF Solutions is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy.

CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.